Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Aortic Stenosis with Normal Flow Low Gradient: Should We Intervene or Wait?

Symptomatic patients with <1 cm² aortic valve area will benefit from an intervention regardless parameters such as flow and gradient, even if these are normal (or at least not severe).

Masa miocárdica fraccional para evaluar la severidad de la estenosisA valve replacement will be indicated without question (either surgical or percutaneous) in patients with >40 mHg mean gradient or low gradient justified by low flow. Much has been said and written about these cases and much will still be written. However, little has been published about patients with normal flow and low gradient.

 

Should we trust aortic valve area blindly when indicating an intervention such as a valve replacement?


Read also: Ten Commandments of the European Hypertension Guidelines: Several “Sins Allowed” Compared with American Guidelines.


Many specialists might question the severity of stenosis in these patients, especially when symptoms can be explained by other causes such as pulmonary or coronary causes.

 

This study included symptomatic patients with ≤ 1 cm² valve area, <40 mmHg mean gradient and > 35 ml/m² stroke volume index.

 

During the study period,1358 patients were assessed, and 303 (34%) met inclusion criteria.


Read also: TAVR Post-dilation Is Safe.


After a mean follow up of nearly 2 years, 60 patients (20%) died, with a global rate of 28%, 10% and 12% in the conservative treatment branch, TAVR and surgery respectively (p<0.001).

 

After adjusting for multiple variables, TAVR was associated with survival improvement vs. the conservative treatment (HR: 0.49; CI 95%:0.26 to 0.93; p=0.03), with no significant differences between surgery and TAVR. What made the difference was the intervention, regardless the type.

 

Conclusion

Symptomatic patients with <1 cm² valve area will benefit from intervention in terms of survival regardless low gradient and normal flow. The type of intervention had no impact on outcomes.

 

Original title: Intervention Versus Observation in Symptomatic Patients with Normal Flow-Low Gradient Severe Aortic Stenosis.

Reference: Oren Zusman et al. J Am Coll Cardiol Img 2018. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...